Statin use and depressive symptoms in a prospective study of community-living older persons

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 9, 2010, Pages 942-948

  Feng, Liang ^a   Yap, Keng Bee ^b   Kua, Ee Heok ^a   Ng, Tze Pin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ALEXANDRA HOSPITAL   (Singapore)

Author keywords

Ageing; Depression; Elderly; Mood; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COMMUNITY LIVING; COMORBIDITY; DEPRESSION; DRUG USE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SYMPTOM;

AGED; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SEX FACTORS; SINGAPORE;

EID: 77957333218     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1993     Document Type: Article

References (24)

1. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
4. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: sub-group analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98: 2513-2519.
5. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN. Risk of macular degeneration in users of statins: cross sectional study. Br Med J 2001; 323: 375-376.
6. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethyl- glutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-2188.
7. Boumendil E, Tubert-Bitter P. Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study using GAZEL cohort data. Epidemiology 1995; 6: 322-325.
8. Hyyppä MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003; 28: 181-194.
9. Stewart RA, Sharpies KJ, North FM, Menkes DB, Baker J, Simes J. Long-term assessment of psychological well being in a randomized placebo controlled trial of cholesterol reduction with pravastatin. Arch Intern Med 2000; 160: 3144-3152.
10. Wardle J, Armitage J, Collins R, et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Br Med J 1996; 313: 75-78.
11. Yang CC, Jick SS, Jick H. Lipid lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003; 163: 1926-1932.
12. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM. .Long-term statin use and psychological well-being. J Am Coll Cardiol 2003; 42: 690-697.
13. Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005; 133: 197-203.
14. Feng L, Tan CH, Merchant RA, Ng TP. Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort. Drugs Aging 2008; 25: 795-805.
15. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007; 55: 420-425.
16. Pasternak RC, Smith SC, Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Stroke 2002; 33: 2337-2341. (Pubitemid 35014654)
17. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006; 113: 372-387.
18. Norwegian Institute of Public Health. Guidelines for ATC Classification and DDD Assignment (7th edn). WHO Collaborating Centre for Drug Statistics Methodology: Oslo, Norway, 2003.
19. Nyunt MSZ, Fones CSL, Niti M, Ng TP. Criterion-based validity and reliability of the Geriatric Depression Screening Scale (GDS-15) in a large validation sample of community-living Asian older adults. Aging Ment Health 2009; 13(3): 376-382.
20. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
21. Glueck CJ, Tieger M, Kunkel R, et al. Improvement in symptoms of depression and in an index of life stressors accompany treatment of severe hypertriglyceridemia. Biol Psychiatry 1993; 34: 240-252.
22. Wirleitner B, Sperner-Unterweger B, Fuchs D. Statins to reduce risk of depression. J Am Coll Cardiol 2004; 43: 1132.
23. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production, tryptophan degradation and mental depression: What is the link? Brain Behav Immun 2002; 16: 590-595.
24. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C. Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology 1996; 15: 465-474.